Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INKmune in MDS-EB or AML
NCT05933070Phase 1Terminated
- Sponsor
- INmune Bio Inc.
- Start
- Jun 2020
- Primary completion
- Mar 2024
- Modality
- Whole Cell Cancer Vaccines, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of INKmune in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), sponsored by INmune Bio Inc. Primary endpoints: Primary Objective 1 and Primary Objective 2. Started Jun 2020; status: terminated.
02
Drugs
INKmune
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05933070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05933070.